Research graph
References from Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis. Local targets link to admitted publications; unresolved targets remain external evidence.
Once-weekly semaglutide in adolescents with obesity
10.1056/nejmoa2208601 · 2022 · External reference
A randomized, controlled trial of liraglutide for adolescents with obesity
10.1056/nejmoa1916038 · 2020 · External reference
Unresolved reference
2025 · External reference
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials
10.1001/jamainternmed.2022.0338 · 2022 · External reference
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · 1981 · External reference
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021 · External reference
Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
10.3389/fphar.2024.1364110 · 2024 · External reference
Acute pancreatitis likely due to semaglutide
10.7759/cureus.69844 · 2024 · External reference
Acute pancreatitis caused by tirzepatide
10.7759/cureus.76007 · 2024 · External reference
